it means that 23andme and glaxosmithkline will make a huge amount of money..n.a. that's being used will make none. they'll be probably charged a lot of money for the drugs if they ever need them. >> wertheim: so we're providing the raw materials to create this product and then we have to pay for the product? >> ikemoto: yeah, that's exactly right. people are now being mined for their raw materials. it raises concerns about what it means to be human in this world. >> anne wojcicki: from the foundation of the company, we have always said, "if our customers can't trust us, we don't have a business." >> wertheim: c.e.o. and founder of 23andme anne wojcicki says her customers are making a conscious decision to contribute their d.n.a. for the benefit of society. >> wojcicki: when we started the company we sat down with the leading privacy experts. and what they taught me was that, "anne, privacy doesn't mean that your data's not shared anywhere." it means that we have choice. >> wertheim: what percent of your customers are opting in and then saying, "go ahead. use

of vir biotech are surging up more than 14% after they announced an expanded partnership with glaxosmithkline >> jon, thanks so much george, it's great to see you this morning you, of course, have been working with glaxosmithkline on a covid antibody drug and are expanding into flu and other respiratory diseases do you think this moment, and one might say it's obvious during a pandemic, but the industries backing away would suggest it's not do you think it signals the pharmaceutical industry is planting a flag because of the threat it exposes of other viruses? >> thank you, meg. i think there is a resurgence of interest i think they're one of the companies that has maintained an interest they're a very big vaccine company and have other programs coming forward we had been working with them the past 10, 11 months on covid. that collaboration has gone extremely well i think jsk has come to appreciate all that vir can do, and it's mutual. we've certainly gotten an appreciate of their capabilities a lot of the work we're doing has implications for other respiratory viruses. it made sense to expan

it's covid vaccine under development with glaxosmithkline will not be available until at least next year. in the meantime, the company will produce its rival's -- its rivals' products. >> the number of a parikh -- the number of americans applying for unemployment benefits dropped slightly for the third week in a row. it is still nearly four times the pre-pandemic weekly average. in total, some 17.8 million people are receiving unemployment benefits. that includes those covered by emergency pandemic programs. employers in the private sector hired far more than anticipated in a sharp turnaround from december's losses. the biden administration continues to work on a $1.9 trillion stimulus relief plan, while republicans have put forward a $600 billion counteroffer. democrats continue to push the legislation through along party lines while president bynum is still hoping for bipartisan support. wall street closed higher, dow jones adding over 300 points by the closing bell. the s&p 500 jumping to a new record closing high. ebay shares rose 5% on stronger-than-expected quarterly results. stock

developed a drug in-house last year that you have licensed and you have this partnership with glaxosmithkline are you most optimistic about potentially curing or treating with the data you have? anne: the thing that is overwhelming about 23andme is the amount of opportunity. we have over 10 million customers routinely do analysis on over 1000 different genotypes. there is a huge amount of research that is undergoing on a regular basis. our first program is an amino oncology program partnered with gsk. really excited about that and the potential. across the whole spectrum of conditions and how we will have an impact. emily: richard, and he plans to get more personally involved? richard: it is possible. through getting out there and talking to a lot of companies, there are a lot of very interesting companies still private that would like to go to the market. we haven't decided whether to invest directly or in the little bit of both. we additionally open to the idea, and i'm sure that our team will explore it. if we can find people like 23andme that are doing some good , then it is likely we wil

. ♪ ♪ vonnie: glaxosmithkline and the jarrow -- in a german biotech have struck a deal to develop nexgen19. they spoke with alix steel and guy johnson. >> there is great work. they are looking into, can it do something like a flu season? with a food -- flu season you don't start with phase 1, 2, 3. we kind of adopt process and we are all learning about. guy: let's talk about the aspects of logistics of making this work. clearly, finishing has been a huge challenge for a lot of people, getting the vaccines out. where are you with it? what are you short of? where are the bottlenecks? >> that is a great question. what you can see is a cross industry effort. there are still unfinished, if you can see it like generic. you need to adopt the processes of course. there has been no manufacturing so far because it was not needed and now we are talking about big quantities, so we have to think about the starting materials, it's was not available because there was no need. the same with the lmp's, the molecule rapidly they rna into. this is what you need to find them as there are three vaccine playe

that's why pfizer, moderna glaxosmithkline and novavax are working on booster specifically for thesee south african variant in the uk variant. those new vaccines, those booster shots to tackle the specific areas will hopefully be out in the next six to eight weeks to protect us but it's so important to take the mitigation efforts and continued them as far as wearing your masks and social distancing until they get those vaccines available to everyone which hopefully by june 1 were expected to have the majority of americans vaccinated. eric bad day can't come soon enough. if you get a vaccine, dr. janette nesheiwat says take precautions and protect yourself and loved ones and everyone else. good to see you dr. janette nesheiwat. arthel: something that will get us relief in 24 hours. super bowl lv. up next a look at everything going on outside the big game in tampa. ♪ ♪ ♪ smooth driving pays off. ♪ with allstate, the safer you drive the more you save. ♪ you never been in better hands. allstate. click or call for a quote today. eric: football fans ready for game day tomorrow in the epic

. >> reporter: today glaxosmithkline announced it's working with a german company to develop vaccineso 100 million doses of its existing vaccine this year. a study from mount sinai hospital suggests people previously infected with covid-19 may only require one vaccine dose to maintain their protection. while the cdc recommends wearing a mask with at least two layers of washable fabric, federal researchers are investigating whether double masking offers additional protection again more infectious mutation. >> there's nothing wrong with people wearing two masks. i often myself wear two masks. can we make a general recommendation that doesn't have scientific basis yet? no. >> reporter: con tack tracers have found many of these variant cases are spread among people wearing no mask and practicing no social distancing. just wearing a mask period is a good place to start. bret? >> bret: jonathan serrie, thank you. parler terminated its ceo john massey according to a memo to staff. the parler board making that decision today without the input of the now former ceo. when republicans had contro

of biotech technology is higher on the news that it is expanding the vaccine technology with glaxosmithklineherapies for other diseases. and wingstop is lower. and other sales of the wing products is the head wing there. and shares of la-z-boy is lower, and with the guy dance of the higher costs of the profit with the company announcing the departure of the ceo at the end of april. and now, let's get a news update from rahel solomon. >> hi, jon. this is what is happening at this hour. let's start with the white house saying that johnson and johnson has a few million of the doses of the vaccine available for distribution and that is despite closing in on the authorization of the food and drug administration. >>> the man who inspired the film "hotel rwanda" is being charged on charges in rwanda. and he is hailed for saving the tutsis in the rwandan genocide. >>> the husband of queen elizabeth, prince philip is being admitted to the hospital and not covid-related. >>> and plants were shutdown thursday due to the utility crisis in texas, and that is not the only issue n. austin, the long lines f

pressure to deliver a covid vaccine after it warned in december the vaccine it was developing with glaxosmithklinean insufficient immune response in older folks. sanofi shares up 2% in the french trade as the biden administration works to ramp up vaccinations in the u.s., the former epicenter of the outbreak, china, has rolled out its own aggressive strategy but the campaign is looking less effective than initially thought. eunice yoon joins us from beijing with the latest there. good evening, eunice >> reporter: good morning, dom, so i'm at a vaccination center, and i'm right outside the entrance you can tell that it's the entrance because there's a qr code where i can take my phone and scan it in order to register right now, 31.2 million people so far have gotten their first injection as of yesterday through these types of centers, and that sounds like a lot, but when you think about how the goal for beijing was to inoculate 50 million people by today, before the lunar new year holiday, you can tell that china is falling a bit short there are a lot of questions as to why that would be you would

mrna vaccine approved during the pandemic, but the company has just announced a partnership with glaxosmithklinedevelop the next generation of vaccines for covid-19. we talked about the supply chain challenges for the company. take a look. >> great work for the regulatory authorities. they are also looking into if you can do something for the flu season. it is an adaptive process, and we are all learning. >> let's talk about all the aspects of the logistics that go into making this work. clearly finishing has been a huge challenge for a lot of people in terms of getting vaccines out. where are you with it? what are your short on right now? >> that's really a great question. what you can see is really a cross-industry effort, what we are doing now. you need to adopt the process, and there has been no big mrna manufacturing so far, and now we are talking about quantities, so we have to think about the starting material to get it from. it was not available at the time because there was no need. same with the lmp. these particles are composed of different components. this is also what you need to fi

>> hi, jim my question is about glaxosmithkline, gsk i bought this as a vaccine and dividend play a coupleths back but with the earnings report coming in mixed earlier this week it's been selling off pretty steadily. i'd love to hear your input on this >> i didn't like it. >> should i keep it or -- >> i don't -- there's no real edge maybe it can get a bit of news bump or something. i've got unbelievable companies like bristol-myers putting up amazing quarters today and the stock didn't go up i would swap glaxo for bristol-myers right here, right now, without a problem i need to go to william in florida, please. william. >> caller: yes, sir, mr. cramer. thank you for taking my call >> of course >> caller: yes, sir. can you hear me? >> you sound about thor than ever, frankly. >> caller: my question is i follow fedex for several months now. i've seen it move from the 34id 100s to just over 300 in november where it seems to be hovering right now is around 240 to 250 after a strong quarter, q2, with revenue up year over year, 18.7, beats on eps by 20% and great quarter in the financials, where

speed led by a controversial former head of vaccine development at the pharmaceutical company glaxosmithkline more vaccines than any company in the world which gave billions of taxpayer dollars to biotech and pharmaceutical companies to speed it up, he singles you out and the president out for appointing you, and he singles all of the team for getting this thing done because every single genius, interest group, university, college, think tank, foundation said it couldn't be done. so i'll just start with that. why do you think biden is trying to phony this up? what's in it? i don't get that. >> well, listen, i frankly have no idea why. i'm surprised. i mean, obviously, the vaccines were approved, two vaccines, in the middle of he's and started to be distributed by january 3rd, if my memory serves me. we have distributed about 14 million doses or almost 20 million doses of the vaccine. and upp til now, more than 70 million doses of vaccine have been distributed, and the plan are exactly as we put them together, to have about 200 million doses distributed by the end of the month of march. and th

glaxosmithkline announcing today will partner to develop a vaccine aimed at targeting new variants of covid-19 vaxart stock is plunging today that company which is developing an experimental coronavirus vaccine in the form of a tablet released disappointing data from the phase one clinical trial showing one dose of the vaccine failed to produce neutralizing antibodies the company says it is now assessing whether there is an antibody response from a second dose promising news on another vaccine. a new study from the university of oxford finding astrazeneca's vaccine not only protects people from illness but substantially slows the transmission of the coronavirus. which is very good news, wilf. >> and suggesting as well that they should be able to develop later styles of the vaccine for new variants by later this year as well which was encouraging to hear time for a cnbc news update. sue herera has it. >> hello everyone. here is what is happening at this hour. in virginia injuries, destroyed cars, and damaged home after a gas line caught fire and exploded a fire department spokesman say

it's being revealed the white house has glaxosmithkline -- guidelines to limit arrests by i.c.e. homan. good morning to you. >> good morning. >> so these guidelines that are circulating, it makes it sound like for the average crime that somebody who is in this country illegally commits, they're not going to get deported. so it's harder to arrest them which means it's harder to he deport them. >> exactly. that's what they're doing, they're circumventing the judge's order. thank god for the ag be in texas who is taking the time and thanks to chip roy, chip row has led a group of senators to send a letter to ask about this. i filed an affidavit with the texas ag explaining the consequences of such a policy. because look, you and i have talked the last couple years, every time that someone's released from a sanctuary jail, they commit a murder or rape, we talk about it for a couple days and it goes away. be clear what's happening here. president biden declared the entire country a sanctuary jurisdiction which means more tragedy is going to come. mark my words. people will die. people

pressure to deliver a vaccine after it warned in december the vaccine it was developing with glaxosmithklineimmune response in older people we're back right after this. i made a business out of my passion. i mean, who doesn't love obsessing over network security? all our techs are pros. they know exactly which parking lots have the strongest signal. i just don't have the bandwidth for more business. seriously, i don't have the bandwidth. glitchy video calls with regional offices? yeah, that's my thing. with at&t business, you do the things you love. our people and network will help do the things you don't. let's take care of business. at&t. this is decision tech. find a stock based on your interests or what's trending. get real-time insights in your customized view of the market. it's smarter trading technology for smarter trading decisions. fidelity. the world's first fully autonomous vehicle is almost at the finish line what a ride! i invested in invesco qqq a fund that invests in the innovators of the nasdaq-100 like you become an agent of innovation with invesco qqq like you labradoodles

we're going to be hearing from biojen and glaxosmithkline, and lots of fed speak spoas well.e minneapolis, and chicago fed presidents f. we get adp today, you know what that ans on friday, jobs reports is coming stay tuned, "squawk box" will be right back when you switch to xfinity mobile, you're choosing to get connected to the most reliable network nationwide, now with 5g included. discover how to save up to $300 a year with shared data starting at $15 a month, or get the lowest price for one line of unlimited. come into your local xfinity store to make the most of your mobile experience. you can shop the latest phones, bring your own device, or trade in for extra savings. stop in or book an appointment to shop safely with peace of mind at your local xfinity store. >>> welcome back, everybody. let's take a look at u.s. equity futures this morning you're going to see green arrows once again these are modest advances. yesterday you did look at significant gains with the dow up by better than 1 1/2%, the nasdaq 2, and the s&p up by about 1.4% this morning, dow futures up 38 po